NOTICE: For the convenience of capital market participants, Chugai makes efforts to provide English translations of the information disclosed in Japanese, provided that the Japanese original prevails over its English translation in the case of any discrepancy found between documentation.

CHUGAI PHARMACEUTICAL CO., LTD.

A member of the Roche group

CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited)

(for the nine months ended September 30, 2025)

Name of Company: Chugai Pharmaceutical Co., Ltd. October 24, 2025
Stock Listing: Tokyo Stock Exchange
Security Code No.: 4519 (URL https://www.chugai-pharm.co.jp/english)
Representative: Osamu Okuda, Representative Director, President & CEO
Contact: Kae Miyata, Head of Corporate Communications Department
Phone: +81-(0)3-3273-0554
Date on which Dividend Payments to Commence: —
Supplementary Materials Prepared for the Financial Statements: Yes
Presentation Held to Explain the Financial Statements: Yes (for institutional investors, securities analysts and the media)

(Note: Amounts of less than one million yen are rounded.)

1. Consolidated results for the nine months ended September 30, 2025

(1) Consolidated operating results

	Revenue	% change	Operating profit	% change	Net income	% change
FY2025 Q3	¥911,640 million	5.0	¥429,827 million	2.7	¥305,602 million	3.3
FY2024 Q3	¥868,538 million	3.7	¥418,602 million	31.8	¥295,758 million	26.2

	Net income attributable to Chugai shareholders	% change	Total comprehensive income	% change
FY2025 Q3	¥305,602 million	3.3	¥287,623 million	(6.8)
FY2024 Q3	¥295,758 million	26.2	¥308,636 million	27.6

	Earnings per share (Basic)	Earnings per share (Diluted)
FY2025 Q3	¥185.70	¥185.70
FY2024 Q3	¥179.75	¥179.72

Note: Percentages represent changes compared with the same period of the previous fiscal year.

(2) Consolidated results (balance sheet)

	Total assets	Total equity	Equity attributable to Chugai shareholders	Ratio of equity attributable to Chugai shareholders
As of Sep. 30, 2025	¥2,183,588 million	¥1,890,107 million	¥1,890,107 million	86.6%
As of Dec. 31, 2024	¥2,208,373 million	¥1,901,499 million	¥1,901,499 million	86.1%

2. Dividends

	Annual dividends per share				
	End of first quarter	End of second quarter	End of third quarter	End of fiscal year	Total
FY ended Dec. 2024	—	¥41.00	—	¥57.00	¥98.00
FY ending Dec. 2025	—	¥125.00	—		
FY ending Dec. 2025 (Forecast)				¥125.00	¥250.00

Notes: 1. Whether the most recent dividend forecast has been revised: No
2. Breakdown of dividends per share at the end of the second quarter of FY ending Dec. 2025:
regular dividend, ¥50.00; special dividend, ¥75.00 (Special dividend for the company's 100th Anniversary)
Breakdown of dividends per share at the end of FY ending Dec. 2025:
regular dividend, ¥50.00; special dividend, ¥75.00 (Special dividend for the company's 100th Anniversary)
Breakdown of annual dividends per share for FY ending Dec. 2025:
regular dividend, ¥100.00; special dividend, ¥150.00 (Special dividend for the company's 100th Anniversary)

3. Consolidated forecasts for the year ending December 31, 2025

	Revenue	% change	Core operating profit	% change	Core net income	% change
FY2025 Q3 (Results)	¥911,640 million	76.6	¥450,526 million	79.0	¥319,996 million	78.0
FY ending Dec. 2025 (Forecast)	¥1,190,000 million	1.7	¥570,000 million	2.5	¥410,000 million	3.2

	Core earnings per share	% change	Core dividend payout ratio %
FY2025 Q3 (Results)	¥194.44	77.8	—
FY ending Dec. 2025 (Forecast)	¥250.00	3.6	100.0

Notes: 1. Except for Core dividend payout ratio, percentages represent changes compared with the same period of the previous fiscal year for the forecasts, and the percentage of forecast levels that have been achieved to date for the results.
2. Whether the most recent forecasts for consolidated figures have been revised: No
3. The figures for the consolidated forecasts and actuals are calculated based on Core basis indicators established by Chugai and used on a consistent basis. Core EPS is diluted earnings per share attributable to Chugai shareholders on a Core basis.

4. Others

(1) Material changes in scope of consolidation during the period: None
(2) Changes in accounting policies and changes in accounting estimates
  (a) Changes in accounting policies required by IFRS: None
  (b) Changes in accounting policies other than those in (a) above: None
  (c) Changes in accounting estimates: None

(3) Number of shares issued (common stock):

(a) Number of shares issued at the end of the period (including treasury stock)	As of Sep. 30, 2025	1,679,057,667	As of Dec. 31, 2024	1,679,057,667
(b) Number of treasury stock at the end of the period	As of Sep. 30, 2025	33,352,901	As of Dec. 31, 2024	33,531,864
(c) Average number of shares issued during the period (nine months)	FY2025 Q3	1,645,644,940	FY2024 Q3	1,645,422,103

Notes:
Review of the Japanese-language originals of the attached consolidated quarterly financial statements by certified public accountants or an audit firm: None

Explanation of the appropriate use of performance forecasts and other related items

(1) Portions of this report that refer to performance forecasts or any other future events are believed to be reasonable under information available at the time of the forecasts. Actual results may differ from these forecasts due to potential risks and uncertainties.
(2) The forecast which is published for shareholders and investors is based on the internal management indicator Core basis under International Financial Reporting Standards ("IFRS"). Core results are the results after adjusting non-recurring items recognized by Chugai to IFRS results. Chugai's recognition of non-recurring items may differ from that of Roche due to the difference in the scale of operations, the scope of business and other factors. Core results are used by Chugai as an indicator for managing internal business performance, explaining the status of recurring profits both internally and externally, and as the basis for payment-by-results such as shareholder returns. The difference between IFRS results and Core results will be explained at each event and presentation for the period.
(3) For the specifics of the forecasts, please refer to "Consolidated forecasts and other forward-looking statements" on page 7 of the attachment.
(4) Chugai is scheduled to hold a presentation of the financial statements as noted below. The presentation materials will be posted on Chugai's website at the time of the third quarter results announcement.
Presentation for institutional investors, securities analysts and the media (Online conference with simultaneous interpretation): Friday, October 24, 2025 (Japan time).
English translation of the scripts including Q&A will be posted on the website within two business days.

Index of the Attachment

1. Qualitative Information 2

(1) Consolidated operating results 2

(2) Consolidated financial position 6

(3) Consolidated forecasts and other forward-looking statements 7

(4) Significant management agreements 7

2. Interim Condensed Consolidated Financial Statements and Major Notes 8

(1) Interim condensed consolidated income statement and interim condensed consolidated statement of comprehensive income 8

(2) Interim condensed consolidated balance sheet 10

(3) Interim condensed consolidated statement of cash flows 11

(4) Interim condensed consolidated statement of changes in equity 12

(5) Notes regarding the going concern assumption 13

(6) Notes to the interim condensed consolidated financial statements 13

1. Qualitative Information

(1) Consolidated operating results in billions of yen

	Nine months ended September 30, 2025	Nine months ended September 30, 2024	% change
Core results			
Revenue	**911.6**	**868.5**	**+5.0**
Sales	794.6	750.3	+5.9
Other revenue	117.1	118.2	(0.9)
Cost of sales	(263.3)	(244.1)	+7.9
Gross profit	**648.3**	**624.4**	**+3.8**
Research and development	(128.8)	(127.9)	+0.7
Selling, general and administration	(69.4)	(72.5)	(4.3)
Other operating income (expense)	0.4	2.4	(83.3)
Operating profit	**450.5**	**426.6**	**+5.6**
Net income	**320.0**	**301.3**	**+6.2**
IFRS results			
Revenue	911.6	868.5	+5.0
Operating profit	429.8	418.6	+2.7
Net income	305.6	295.8	+3.3

Consolidated financial highlights (IFRS results)
Revenue for the nine months under review was ¥911.6 billion (an increase of 5.0% year on year), operating profit for the nine months under review was ¥429.8 billion (an increase of 2.7% year on year), and net income for the nine months under review was ¥305.6 billion (an increase of 3.3% year on year). These results include non-Core items, which are excluded from the Core results that Chugai adopts to manage recurring business activities, such as amortization of intangible assets of ¥1.1 billion, impairment loss of intangible assets of ¥0.1 billion, business rebuilding expenses of ¥10.2 billion, expenses relating to the management decision to collectively discontinue in-house development projects, etc. of ¥17.8 billion, and restructuring expenses of ¥8.4 billion (income), including gain on sales of non-current assets in conjunction with the closing of a business office.

Consolidated financial highlights (Core results)
Revenue for the nine months under review was ¥911.6 billion (an increase of 5.0% year on year), due to an increase in sales.

Of revenue, sales were ¥794.6 billion (an increase of 5.9% year on year). Domestic sales exceeded the levels of the same period of the previous fiscal year due to the increase in the sales of new products Phesgo and PiaSky, and the mainstay products Vabysmo, Hemlibra, and Enspryng, despite the effects of the NHI drug price revisions and the market penetration of generic drugs. Overseas sales increased compared to the same period of the previous fiscal year, due to the significant increase in the export of Actemra to Roche. Other revenue was ¥117.1 billion (a decrease of 0.9% year on year) due to the decrease in one-time income and other factors, despite the increase in income related to Hemlibra. Furthermore, cost to sales ratio was 33.1%, a 0.6 percentage point rise year on year, reflecting a change in product mix and other factors. As a result, gross profit amounted to ¥648.3 billion (an increase of 3.8% year on year).

Research and development expenses were ¥128.8 billion (an increase of 0.7% year on year) due to increases associated with investments into drug discovery/early development and the progress of development projects, etc., and selling, general and administration expenses were ¥69.4 billion (a decrease of 4.3% year on year) due to a decrease in various expenses. Other operating income (expense) was income of ¥0.4 billion (¥2.4 billion of income for the same period of the previous fiscal year). As a result, core operating profit was ¥450.5 billion (an increase of 5.6% year on year) and core net income was ¥320.0 billion (an increase of 6.2% year on year).

Note: Core results
Chugai discloses its results on a Core basis from 2013 in conjunction with its transition to IFRS. Core results are the results after adjusting non-recurring items recognized by Chugai to IFRS results. Chugai's recognition of non-recurring items may differ from that of Roche due to the difference in the scale of operations, the scope of business and other factors. Core results are used by Chugai as an internal performance indicator, for explaining the status of recurring profits both internally and externally, and as the basis for payment-by-results.

For further details regarding the adjustment to IFRS results, please refer to Supplementary Materials Consolidated Financial Statements for the nine months ended September 30, 2025 (IFRS), dated October 24, 2025, on page 1, entitled "Reconciliation of IFRS results to Core results."

Sales breakdown in billions of yen

	Nine months ended September 30, 2025	Nine months ended September 30, 2024	% change
Sales	**794.6**	**750.3**	**+5.9**
Domestic sales	**343.7**	**331.7**	**+3.6**
Oncology	180.7	180.3	+0.2
Specialty	163.0	151.3	+7.7
Overseas sales	**450.9**	**418.7**	**+7.7**

Domestic sales
Domestic sales were ¥343.7 billion (an increase of 3.6% year on year) due to the sales growth of new products and mainstay products, despite the effects of the NHI drug price revisions and the market penetration of generic drugs.

Oncology products sales were ¥180.7 billion (an increase of 0.2% year on year). Sales of the mainstay product Avastin (an anti-VEGF humanized monoclonal antibody, anti-cancer agent) decreased due to the effects of the NHI drug price revisions and the market penetration of generic drugs. In addition, sales of Perjeta (an anti-HER2 humanized monoclonal antibody, anti-cancer agent) decreased significantly, mainly due to the ongoing replacement of Perjeta with the new product Phesgo (antineoplastic agent/anti-HER2 humanized monoclonal antibody/hyaluronan-degradation enzyme combination drug), a subcutaneous combination drug containing Perjeta. Meanwhile, in addition to the significant increase in sales of Phesgo, the mainstay product Polivy (an antimicrotubule binding anti-CD79b monoclonal antibody, anti-cancer agent) performed strongly, while the market penetration of Lunsumio (antineoplastic agent/anti-CD20/CD3 humanized bispecific monoclonal antibody), launched in March 2025 was also favorable.

Specialty products sales were ¥163.0 billion (an increase of 7.7% year on year). This was primarily due to the strong sales of the mainstay product Vabysmo (an ophthalmic VEGF/Ang-2 inhibitor, anti-VEGF/anti-Ang-2 humanized bispecific monoclonal antibody), Hemlibra (a blood coagulation factor VIII substitute/anti-coagulation factor IXa/X humanized bispecific monoclonal antibody) and Enspryng (pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody), as well as the favorable market penetration of the new product PiaSky (a pH-dependent binding humanized anti-complement (C5) monoclonal antibody), despite the effects of the NHI drug price revisions and the market penetration of generic drugs.

Overseas sales
Overseas sales amounted to ¥450.9 billion (an increase of 7.7% year on year). In terms of exports to Roche, sales of Actemra (a humanized anti-human IL-6 receptor monoclonal antibody) significantly grew from the same period of the previous fiscal year.

R&D activities

R&D expenses on a Core basis for the first nine months under review totaled ¥128.8 billion (an increase of 0.7% year on year), and the ratio of R&D expenses to revenue was 14.1%.

Progress made in R&D activities during the period from January 1, 2025 to September 30, 2025 was as follows.

Oncology

- We obtained approval for an antineoplastic agent/humanized anti-PD-L1 monoclonal antibody RG7446 (Product name: Tecentriq) for an additional indication of unresectable alveolar soft part sarcoma in February 2025 and relapsed or refractory extranodal NK/T-cell lymphoma, nasal type in September 2025, respectively. Additionally, we filed for RG7446 for an additional indication of the treatment of unresectable thymic carcinoma in May 2025. We also decided to discontinue the domestic development of RG7446 for prostate cancer (2nd Line) (in combination with cabozantinib) in consideration of the results of global Phase III study CONTACT-02. Besides, we decided to discontinue the development for early breast cancer (perioperative) in consideration of the results of prior clinical studies.
- We filed for an antineoplastic agent/ALK inhibitor AF802/RG7853 (Product name: Alecensa) for an additional indication of the treatment of *ALK* fusion/rearrangement gene-positive unresectable advanced or recurrent solid tumors in June 2025.
- We filed for an antineoplastic agent/humanized anti-CD20/CD3 bispecific antibody RG7828 (Product name: Lunsumio) for an additional indication of the treatment of relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma, in combination with Polivy in May 2025.
- We filed for an anti-cancer agent/humanized anti-VEGF monoclonal antibodyRG435 (Product name: Avastin) for an additional indication of the treatment of neurofibromatosis type 2 in August 2025.
- We started domestic Phase II study for an anti-CD20/CD3 bispecific antibody RG6026 for the treatment of relapsed or refractory diffuse large B-cell lymphoma and relapsed or refractory mantle cell lymphoma in August 2025.
- We started domestic Phase I/II study for a PI3Kα inhibitor RG6114 for the treatment of *PIK3CA*-mutated breast cancer in combination with palbociclib and fulvestrant in July 2025.
- We started Phase I study for MINT91 for the treatment of solid tumors in April 2025.
- We started Phase I study for a pan-KRAS inhibitor AUBE00 for the treatment of solid tumors in June 2025.
- We decided to discontinue the development of an anti-TIGIT human monoclonal antibody RG6058 for non-small cell lung cancer (1st Line), non-small cell lung cancer (stage III), esophageal cancer, all in combination with Tecentriq, and hepatocellular carcinoma (1st Line) in combination with Tecentriq and Avastin, considering the results of global Phase III studies SKYSCRAPER-01, SKYSCRAPER-03, SKYSCRAPER-07, and SKYSCRAPER-14, respectively.
- We decided to discontinue the development of an anti-HER2/CD3 bispecific antibody RG6194 for solid tumors in consideration of business strategy.
- We decided to discontinue the development of an anti-VEGF (Vascular Endothelial Growth Factor) humanized monoclonal antibody RG435 (Product name: Avastin) for small cell lung cancer (1st Line) in combination with Tecentriq, considering the results of Phase III study BEAT-SC.
- We made a management decision to discontinue the in-house development of a RAS inhibitor LUNA18, considering obtained data up to date and the portfolio status.
- We made a management decision to discontinue the in-house development of an anti-CD137 agonistic switch antibody STA551, considering obtained data up to date and the portfolio status.
- We made a management decision to discontinue the in-house development of an anti-latent TGF-β1 monoclonal antibody SOF10, considering obtained data up to date and the portfolio status.
- We made a management decision to discontinue the in-house development of an anti-CLDN6/CD3/CD137 trispecific antibody SAIL66, considering obtained data up to date and the portfolio status.

Immunology

- We filed for an immunosuppressant (Product name: CellCept) based on public knowledge in March 2025 and obtained approval for an additional indication of refractory nephrotic syndrome (frequently relapsing or steroid-dependent nephrotic syndrome) in September 2025.
- We started global Phase III study for an anti-TL1A antibody RG6631 for the treatment of ulcerative colitis in April 2025 and Crohn's disease in September 2025.

Neuroscience

- We obtained approval for a viral vector product RG6356/SRP-9001 (Product name: Elevidys) as a regenerative medicine product for the treatment of Duchenne muscular dystrophy (DMD) (ambulatory patients with DMD who do not have a deletion of any portion or the entirety of exon 8 and/or exon 9 in the *DMD* gene, are negative for anti-AAVrh74 antibodies, and are 3 years to less than 8 years of age) under the conditional and time-limited approval pathway in Japan in May 2025.
- We started Phase II study for a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody SA237/RG6168 (Product name: Enspryng) for the treatment of Duchenne muscular dystrophy (DMD) in April 2025.

Hematology

- We started global Phase III study for a blood coagulation factor VIII substitute/anti-coagulation factor IXa/X humanized bispecific monoclonal antibody ACE910/RG6013 (Product name: Hemlibra) for the treatment of type 3 von Willebrand disease in June 2025.
- We decided to remove a pH-dependent binding humanized anti-complement (C5) monoclonal antibody SKY59/RG6107 (Product name: PiaSky) for the treatment of sickle cell disease from the pipeline following the decision made by Roche to discontinue the development, considering the results of overseas study.

Ophthalmology

- We obtained approval for an ophthalmic VEGF/Ang-2 inhibitor, anti-VEGF/anti-Ang-2 humanized bispecific monoclonal antibody RG7716 (Product name: Vabysmo) for an additional indication of the treatment of choroidal neovascularization associated with angioid streaks in May 2025. We also started domestic Phase III study for the treatment of non-proliferative diabetic retinopathy in May 2025.

Other Diseases

- We started Phase I study for an anti-C1s recycling antibody RAY121 in March 2025.
- We started Phase II study for an anti-latent myostatin sweeping antibody GYM329/RG6237 for the treatment of obesity in May 2025.
- We made a management decision to discontinue the in-house development of an anti-IL-8 recycling antibody AMY109, considering obtained data up to date and the portfolio status.

(2) Consolidated financial position

Assets, liabilities and net assets in billions of yen

	September 30, 2025	December 31, 2024	Change in amount
Net operating assets (NOA) and Net assets			
Net working capital	468.7	448.7	20.0
Long-term net operating assets	542.3	498.9	43.4
Net operating assets (NOA)	**1,011.0**	**947.6**	**63.4**
Net cash	882.4	996.3	(113.9)
Other non-operating assets – net	(3.3)	(42.5)	39.2
Total net assets	**1,890.1**	**1,901.5**	**(11.4)**
Consolidated balance sheet (IFRS basis)			
Total assets	2,183.6	2,208.4	(24.8)
Total liabilities	(293.5)	(306.9)	13.4
Total net assets	1,890.1	1,901.5	(11.4)

Net operating assets (NOA) as of September 30, 2025 were ¥1,011.0 billion, an increase of ¥63.4 billion since the end of the previous fiscal year. Of NOA, net working capital was ¥468.7 billion, an increase of ¥20.0 billion from the end of the previous fiscal year, due mainly to an increase in trade accounts receivable and a decrease in accounts payable for purchase of property, plant and equipment, etc., despite an increase in trade accounts payable. Long-term net operating assets increased by ¥43.4 billion to ¥542.3 billion since the end of the previous fiscal year, mainly due to the investments in the manufacturing building for bio drug substance (UT3) and the injection building (UTA) in the Utsunomiya Plant, and an increase in intangible assets.

As indicated in “Cash flows” on the next page, net cash, including marketable securities and interest-bearing debt, decreased by ¥113.9 billion since the end of the previous fiscal year to ¥882.4 billion. Other non-operating assets – net increased by ¥39.2 billion since the end of the previous fiscal year to ¥(3.3) billion due mainly to a decrease in current income tax liabilities.

As a consequence, total net assets were ¥1,890.1 billion (a decrease of ¥11.4 billion since the end of the previous fiscal year).

Note: Net operating assets (NOA) and Net assets
The consolidated balance sheet has been prepared in accordance with International Accounting Standards (IAS) No. 1, “Presentation of Financial Statements.” On the other hand, Net operating assets (NOA) and Net assets are a reconfiguration of the consolidated balance sheet as internal indicators and are identical to the indicators disclosed by Roche. Furthermore, no items from Net operating assets (NOA) and Net assets have been excluded, as the Core results concept only applies to the income statement.

For further details, please refer to the Supplementary Materials on page 8, entitled “Financial position.”

Note: Net operating assets (NOA)
Net operating assets allow for an assessment of the Group’s operating performance of the business independently from financing and tax activities. Net operating assets are calculated as net working capital, long-term net operating assets that includes property, plant and equipment, intangible assets etc. minus provisions.

Cash flows in billions of yen

	Nine months ended September 30, 2025	Nine months ended September 30, 2024	% change
Free cash flows			
Operating profit - IFRS basis	429.8	418.6	+2.7
Operating profit, net of operating cash adjustments	472.9	444.5	+6.4
Operating free cash flows	373.2	347.4	+7.4
Free cash flows	**181.2**	**238.2**	**(23.9)**
Net change in net cash	(113.9)	106.3	―
Consolidated statement of cash flows (IFRS basis)			
Cash flows from operating activities	257.2	295.2	(12.9)
Cash flows from investing activities	(39.5)	(210.5)	(81.2)
Cash flows from financing activities	(305.6)	(139.0)	+119.9
Net change in cash and cash equivalents	(83.8)	(54.7)	+53.2
Cash and cash equivalents at September 30	456.4	404.0	+13.0

Operating profit, net of operating cash adjustments, amounted to ¥472.9 billion (an increase of 6.4% year on year), which was calculated by adjusting for depreciation and other items that are included in operating profit but are not accompanied by cash inflows or outflows and all inflows and outflows related to NOA that are not accompanied by profit and loss.

Operating free cash flows for the nine months under review amounted to a net inflow of ¥373.2 billion (an increase of 7.4% year on year) mainly due to deducting an expenditure of ¥58.9 billion for the purchase of property, plant and equipment from operating profit, net of operating cash adjustments, in addition to an increase in net working capital, etc. of ¥17.5 billion. Factors accounting for the increase in net working capital, etc. are as indicated in "Assets, liabilities and net assets" on the previous page.

Free cash flows were a net cash inflow of ¥181.2 billion (a decrease of 23.9% year on year) due mainly to income taxes paid of ¥190.7 billion from operating free cash flows.

The net change in net cash calculated by adjusting for dividends paid of ¥299.5 billion, etc. from free cash flows was a decrease of ¥113.9 billion.

The net change in cash and cash equivalents, excluding changes in marketable securities and interest-bearing debt, was a net cash outflow of ¥83.8 billion. The cash and cash equivalents balance at the end of this period amounted to ¥456.4 billion.

Note: Free cash flows (FCF)
The consolidated statement of cash flows has been prepared in accordance with International Accounting Standard (IAS) No. 7, "Statement of Cash Flows." FCF is a reconfiguration of the consolidated statement of cash flows as internal indicators and is identical to the indicators disclosed by Roche. Furthermore, no items from FCF have been excluded, as the Core results concept only applies to the income statement.

For further details, please refer to the Supplementary Materials on page 9, entitled "Cash flows."

(3) Consolidated forecasts and other forward-looking statements
Chugai has not made any changes in its forecast of consolidated results for the fiscal year ending December 31, 2025 since the announcement regarding the forecast issued on January 30, 2025.

(4) Significant management agreements
No significant management agreements were decided on or concluded during the third quarter of the fiscal year 2025.

Note: In "1. Qualitative Information," amounts less than ¥0.1 billion have been rounded to the nearest ¥0.1 billion. Figures for changes in amounts and percentages have been calculated using data denominated in ¥0.1 billion units.

2. Interim Condensed Consolidated Financial Statements and Major Notes

(1) Interim condensed consolidated income statement and interim condensed consolidated statement of comprehensive income

1) Interim condensed consolidated income statement in millions of yen

	Nine months ended September 30	
	2025	2024
Revenue	**911,640**	**868,538**
Sales	794,586	750,326
Other revenue	117,054	118,212
Cost of sales	(276,131)	(245,108)
Gross profit	**635,509**	**623,430**
Research and development	(135,192)	(129,212)
Selling, general and administration	(79,536)	(77,680)
Other operating income (expense)	9,046	2,064
Operating profit	**429,827**	**418,602**
Financing costs	(112)	5
Other financial income (expense)	(1,813)	(1,080)
Profit before taxes	**427,902**	**417,527**
Income taxes	(122,299)	(121,769)
Net income	**305,602**	**295,758**
Attributable to:		
Chugai shareholders	305,602	295,758
Earnings per share		
Basic (yen)	185.70	179.75
Diluted (yen)	185.70	179.72

2) Interim condensed consolidated statement of comprehensive income in millions of yen

	Nine months ended September 30	
	2025	2024
Net income recognized in income statement	**305,602**	**295,758**
Other comprehensive income		
Remeasurements of defined benefit plans	(12)	37
Financial assets measured at fair value through OCI	55	(23)
Items that will never be reclassified to the income statement	**44**	**14**
Financial assets measured at fair value through OCI	2	6
Cash flow hedges	(22,370)	11,737
Currency translation of foreign operations	4,345	1,122
Items that are or may be reclassified to the income statement	**(18,023)**	**12,864**
Other comprehensive income, net of tax	**(17,979)**	**12,878**
Total comprehensive income	**287,623**	**308,636**
Attributable to:		
Chugai shareholders	287,623	308,636

(2) Interim condensed consolidated balance sheet in millions of yen

	September 30, 2025	December 31, 2024
Assets		
Non-current assets:		
Property, plant and equipment	449,610	433,129
Right-of-use assets	13,540	8,425
Intangible assets	34,164	17,868
Deferred tax assets	82,885	69,835
Defined benefit plan assets	14,024	13,978
Other non-current assets	71,635	59,094
Total non-current assets	**665,859**	**602,330**
Current assets:		
Inventories	246,326	240,067
Accounts receivable	353,649	334,256
Current income tax assets	205	896
Marketable securities	426,015	456,143
Cash and cash equivalents	456,432	540,202
Other current assets	35,103	34,479
Total current assets	**1,517,730**	**1,606,043**
Total assets	**2,183,588**	**2,208,373**
Liabilities		
Non-current liabilities:		
Deferred tax liabilities	(4,551)	(5,076)
Defined benefit plan liabilities	(4,378)	(3,935)
Long-term provisions	(5,026)	(2,188)
Other non-current liabilities	(12,103)	(5,319)
Total non-current liabilities	**(26,058)**	**(16,516)**
Current liabilities:		
Current income tax liabilities	(43,365)	(108,732)
Short-term provisions	(3,695)	(2,974)
Accounts payable	(78,897)	(65,353)
Other current liabilities	(141,466)	(113,298)
Total current liabilities	**(267,423)**	**(290,357)**
Total liabilities	**(293,481)**	**(306,873)**
Total net assets	**1,890,107**	**1,901,499**
Equity:		
Capital and reserves attributable to Chugai shareholders	1,890,107	1,901,499
Total equity	**1,890,107**	**1,901,499**
Total liabilities and equity	**2,183,588**	**2,208,373**

(3) Interim condensed consolidated statement of cash flows in millions of yen

	Nine months ended September 30	
	2025	2024
Cash flows from operating activities		
Cash generated from operations	471,417	448,943
(Increase) decrease in working capital	(17,502)	(38,011)
Payments made for defined benefit plans	(1,734)	(2,311)
Utilization of provisions	(3,561)	(3,090)
Other operating cash flows	(745)	(9,903)
Cash flows from operating activities, before income taxes paid	**447,876**	**395,629**
Income taxes paid	(190,703)	(100,423)
Total cash flows from operating activities	**257,173**	**295,206**
Cash flows from investing activities		
Purchase of property, plant and equipment	(58,902)	(50,159)
Purchase of intangible assets	(17,327)	(2,862)
Disposal of property, plant and equipment	7,285	(450)
Disposal of intangible assets	28	1,707
Interest and dividends received	2,521	2,189
Purchases of marketable securities	(895,460)	(725,000)
Sales of marketable securities	925,630	565,390
Purchases of investment securities	(3,325)	(1,277)
Total cash flows from investing activities	**(39,549)**	**(210,462)**
Cash flows from financing activities		
Interest paid	(286)	(70)
Lease liabilities paid	(5,932)	(6,089)
Dividends paid to Chugai shareholders	(299,542)	(132,959)
Exercise of equity compensation plans	130	152
(Increase) decrease in own equity instruments	(3)	(9)
Total cash flows from financing activities	**(305,632)**	**(138,975)**
Net effect of currency translation on cash and cash equivalents	4,238	(486)
Increase (decrease) in cash and cash equivalents	**(83,770)**	**(54,716)**
Cash and cash equivalents at January 1	540,202	458,674
Cash and cash equivalents at September 30	**456,432**	**403,958**

(4) Interim condensed consolidated statement of changes in equity in millions of yen

For the nine months ended September 30, 2024

	Attributable to Chugai shareholders					
	Share capital	Capital surplus	Retained earnings	Other reserves	Subtotal	Total equity
As of January 1, 2024	**73,202**	**69,355**	**1,488,738**	**(5,715)**	**1,625,580**	**1,625,580**
Net income	—	—	295,758	—	295,758	295,758
Financial assets measured at fair value through OCI	—	—	—	(17)	(17)	(17)
Cash flow hedges	—	—	—	11,737	11,737	11,737
Currency translation of foreign operations	—	—	—	1,122	1,122	1,122
Remeasurements of defined benefit plans	—	—	37	—	37	37
Total comprehensive income	**—**	**—**	**295,795**	**12,842**	**308,636**	**308,636**
Dividends	—	—	(133,277)	—	(133,277)	(133,277)
Equity compensation plans	—	(58)	—	—	(58)	(58)
Own equity instruments	—	486	—	—	486	486
As of September 30, 2024	**73,202**	**69,783**	**1,651,256**	**7,127**	**1,801,367**	**1,801,367**

For the nine months ended September 30, 2025

	Attributable to Chugai shareholders					
	Share capital	Capital surplus	Retained earnings	Other reserves	Subtotal	Total equity
As of January 1, 2025	**73,202**	**69,896**	**1,746,934**	**11,468**	**1,901,499**	**1,901,499**
Net income	—	—	305,602	—	305,602	305,602
Financial assets measured at fair value through OCI	—	—	—	58	58	58
Cash flow hedges	—	—	—	(22,370)	(22,370)	(22,370)
Currency translation of foreign operations	—	—	—	4,345	4,345	4,345
Remeasurements of defined benefit plans	—	—	(12)	—	(12)	(12)
Total comprehensive income	**—**	**—**	**305,591**	**(17,968)**	**287,623**	**287,623**
Dividends	—	—	(299,508)	—	(299,508)	(299,508)
Equity compensation plans	—	(6)	—	—	(6)	(6)
Own equity instruments	—	499	—	—	499	499
As of September 30, 2025	**73,202**	**70,389**	**1,753,017**	**(6,500)**	**1,890,107**	**1,890,107**

(5) Notes regarding the going concern assumption

None

(6) Notes to the interim condensed consolidated financial statements

1) General accounting principles and significant accounting policies

a. Basis of preparation of the consolidated financial statements

These financial statements are the interim condensed consolidated financial statements ("Interim Financial Statements") of Chugai, a company registered in Japan, and its subsidiaries ("the Group"). The common stock of Chugai is publicly traded and listed on the Tokyo Stock Exchange under the stock code "TSE: 4519." The Interim Financial Statements were approved by the Board of Directors on October 24, 2025.

Roche Holding Ltd. is a public company registered in Switzerland and the parent company of the Roche Group, which discloses its results in accordance with IFRS. The shareholding percentage of Roche Holding Ltd. in Chugai is 59.89% (61.10% of the total number of shares issued excluding treasury stock). The Group became principal members of the Roche Group after entering into a strategic alliance in October 2002.

The Group has prepared the Interim Financial Statements in accordance with Article 5, Paragraph 2 of the Standards for the Preparation of Quarterly Financial Statements, etc. of Tokyo Stock Exchange, Inc. However, in accordance with Article 5, Paragraph 5 of the Standards for the Preparation of Quarterly Financial Statements, etc., some disclosures in International Accounting Standard (IAS) No. 34 "Interim Financial Reporting" have been omitted.

The Interim Financial Statements should be used with the consolidated financial statements for the year ended December 31, 2024 as they do not include all the information as required for the consolidated financial statements for the full fiscal year.

The Interim Financial Statements are presented in Japanese yen, which is Chugai's functional currency and amounts are rounded to the nearest ¥1 million. They have been prepared using the historical cost convention except for items that are required to be accounted for at fair value.

b. Key accounting judgments, estimates and assumptions

The preparation of the Interim Financial Statements requires management to make judgments, estimates, and assumptions that affect the reported amounts of revenue, expenses, assets, liabilities, and contingent amounts. Actual outcomes could differ from those management estimates. The estimates and underlying assumptions are reviewed on an on-going basis and are based on historical experience and various other factors. Revisions to estimates are recognized in the period in which the estimate is revised.

The information for judgment, estimates, and assumptions that have a material impact on the amount recognized in the Interim Condensed Financial Statements of the Group is principally the same for the prior fiscal year.

However, should the situation persist, it could result in such risks as major revisions of the carrying amounts of assets and liabilities in the following fiscal year and beyond.

c. Changes in accounting policies

The Group applies the same significant accounting policies that were applied to the Interim Financial Statements of the previous fiscal year.

Although minor changes have been made to certain accounting standards, they do not have a material impact on the Group's overall results and financial position.

2) Operating segment information

The Group has a single business of pharmaceuticals and does not have multiple operating segments. The Group's pharmaceuticals business consists of research and development of new prescription medicines and subsequent manufacturing, marketing and distribution activities. These functional activities are integrated and managed effectively.

Information on revenue by geographical area in millions of yen

	Nine months ended September 30			
	2025		2024	
	Sales	Other revenue	Sales	Other revenue
Japan	343,734	1,275	331,665	1,346
Overseas	450,852	115,779	418,661	116,866
of which Switzerland	426,734	115,125	395,668	115,906
Total	**794,586**	**117,054**	**750,326**	**118,212**

Information on revenue by major customers in millions of yen

	Nine months ended September 30	
	2025	2024
F. Hoffmann-La Roche Ltd.	526,080	490,162
Alfresa Holdings Corporation and its affiliates	110,811	100,399

3) Related parties

Dividends

The dividends distributed to Roche by Chugai in respect to its holdings of Chugai shares totaled ¥183,032 million as of September 30, 2025 (2024:¥81,459 million).

Material transactions and balances with related parties

Transactions with F. Hoffmann-La Roche in millions of yen

	Nine months ended September 30	
	2025	2024
Revenue	526,080	490,162
Purchases	144,397	125,139

Balances with F. Hoffmann-La Roche in millions of yen

	September 30, 2025	December 31, 2024
Accounts receivable	216,825	201,957
Trade accounts payable	27,690	7,327

4) Subsequent events

Chugai has resolved, at a meeting of the Board of Directors held on October 24, 2025, to acquire all shares and stock acquisition rights (hereinafter "Share Acquisition") of Renalys Pharma, Inc. (Headquarters: Tokyo, Representative Director: Brian Taylor Slingsby, hereinafter "Renalys Pharma"), a domestic bioventure company, and thereby obtain the exclusive development and commercialization rights in Japan, South Korea, and Taiwan, for sparsentan, which is being developed mainly for IgA nephropathy (hereinafter "the Acquisition"). The execution of this Share Acquisition is scheduled to take place during the current fourth quarter accounting period.

a. Reason for acquisition

Renalys Pharma was established for the purpose of developing and commercializing sparsentan, which is being developed mainly for IgA nephropathy in Asia. Chugai has decided the Share Acquisition in order to obtain the exclusive development and commercialization rights for sparsentan in Japan, South Korea, and Taiwan.

IgA nephropathy is one of the designated intractable diseases in Japan. Existing medicinal treatments may not provide sufficient efficacy in some cases, indicating unmet medical needs.

Chugai has sefaxersen (an antisense oligonucleotide targeting *complement factor* B mRNA), which is currently in the global Phase III clinical trial as a treatment for IgA nephropathy. Based on their different mechanism of action, sefaxersen and sparsentan are expected to have different positioning in clinical practice. By having these two agents, Chugai aims to provide a broader range of treatment approaches for patients with IgA nephropathy.

The Acquisition is part of our strategic investment aimed at providing innovative products and services, and by acquiring the development and commercialization rights for sparsentan, a promising development project, in Japan, South Korea, and Taiwan, and by strengthening our pipeline in IgA nephropathy and other kidney diseases, we aim to further contribute to patients and healthcare professionals, as well as further enhance our corporate value and shareholder value.

b. Consideration and method for acquisition

The consideration for the Acquisition consists of (1) a one-time payment to be made at the time of the Share Acquisition (hereinafter "Closing Consideration") and (2) payments based on the progress of sparsentan regulatory approval and future revenue (hereinafter "Earn-out Consideration"). The details of the Closing Consideration and Earn-out Consideration are as follows:

(1) Closing Consideration

On the date when the Share Acquisition is executed (hereinafter "Closing Date"), Chugai will pay the Seller a Closing Consideration of 15,000 million JPY in cash, plus an amount reflecting price adjustment under the Share Purchase Agreement.

(2) Earn-out Consideration

Chugai will pay the Seller milestone payments of up to 16,000 million JPY based on multiple milestones according to the progress of sparsentan regulatory approval, and consideration linked to sparsentan's net sales in Japan, South Korea, and Taiwan, in cash.

c. Overview of Renalys Pharma, Inc.

(1) Name	Renalys Pharma, Inc.
(2) Location	2-3-11 Nihonbashi-honcho, Chuo-ku, Tokyo
(3) Job title and name of representative	Representative Director (CEO): Brian Taylor Slingsby
(4) Description of business	Research and Development, and marketing of Pharmaceuticals
(5) Date of establishment	April, 2023